Publications & Presentations

cdk2b

Our scientists are recognised as world leaders in fragment-based discovery. Some of their influential publications and upcoming engagements at major conferences are listed below.

Selected publication highlights are:

 

1.

Off-Rate Screening (ORS) By Surface Plasmon Resonance. An Efficient Method to Kinetically Sample Hit to Lead Chemical Space from Unpurified Reaction Products. James B. Murray, Stephen D. Roughley, Natalia Matassova, and Paul A. Brough J. Med. Chem., Articles ASAP (As Soon As Publishable) Publication Date (Web): February 12, 2014 (Brief Article) DOI: 10.1021/jm401848a.

2.  Hsp90 inhibitors and drugs from fragment and virtual screening, Roughley SD, Wright L, Brough P, Massey A, Hubbard RE Top Curr Chem. 2012:317:61-82 PMID: 21647838.

3.  The Medicinal Chemist's Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates. Roughley SD, Jordan AM. J Med Chem. 2011 May 26;54(10):3451-79. PMID: 21504168.

4.  Experiences in fragment-based lead discovery. Hubbard RE, Murray JB. Methods Enzymol. 2011;493:509-31. PMID: 21371604.

5.  How Well Can Fragments Explore Accessed Chemical Space? A Case Study from Heat Shock Protein 90. Roughley SD, Hubbard RE.J Med Chem. 2011 May 24. [Epub ahead of print] No abstract available. PMID: 21561141 [PubMed - as supplied by publisher] Related citations.

6. Chen IJ, Foloppe N. Drug-like bioactive structures and conformational coverage with the LigPrep/ConfGen suite: comparison to programs MOE and catalyst. J Chem Inf Model. 2010 May 24;50(5):822-39. PubMed PMID: 20423098.

7. Brough, P.A. et al (2009), "Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone", J Med Chem, 52, 4794-4809.

 

 

Latest News

Vernalis achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc

Vernalis plc is pleased to announce the achievement of a clinical milestone from its collaboration with Corvus Pharmaceuticals Inc ("Corvus") triggering a payment of $3 million to Vernalis.

Read more ...

Product Pipeline

For more information on our pipeline, click below to visit Vernalis plc

Commercial Pipeline

Comm-thumbnailExplore the pipeline ...

 

NCE Pipeline

NCE-thumbnailExplore the pipeline ...

 

Contact Vernalis Research

T: (0)1223 895555
F: (0)1223 895556

Contact information
Maps and directions
Contact form

Fact Sheet

For more information on Vernalis, click on the below image to download a copy of our fact sheet

Vernalis Factsheet May 2015 Page 1